PLoS ONE (Jan 2019)

Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.

  • Hiroki Harada,
  • Kei Hosoda,
  • Hiromitsu Moriya,
  • Hiroaki Mieno,
  • Akira Ema,
  • Hideki Ushiku,
  • Marie Washio,
  • Nobuyuki Nishizawa,
  • Satoru Ishii,
  • Kazuko Yokota,
  • Yoko Tanaka,
  • Takeshi Kaida,
  • Takafumi Soeno,
  • Yoshimasa Kosaka,
  • Masahiko Watanabe,
  • Keishi Yamashita

DOI
https://doi.org/10.1371/journal.pone.0214872
Journal volume & issue
Vol. 14, no. 4
p. e0214872

Abstract

Read online

BackgroundThere have been few available prognostic biomarkers in gastric cancer. We rigorously assessed the clinical relevance of promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene, a cancer-specific aberration, in human gastric cancer.MethodsQuantitative CDO1 methylation value (TaqMeth V) was initially calculated in 138 gastric cancer patients operated in 2005, and its clinical significance was elucidated. As a subsequent expanded set, 154 gastric cancer patients with pathological stage (pStage) II / III with no postoperative therapy were validated between 2000 and 2010.Results(1) Median TaqMeth V of CDO1 gene methylation of gastric cancer was 25.6, ranging from 0 to 120.9. As pStage progressed, CDO1 TaqMeth V became higher (p ConclusionsPromoter DNA hypermethylation of CDO1 gene was rigorously validated as an important prognostic biomarker in primary gastric cancer with specific stage.